Synergy between Group 2 capsules and lipopolysaccharide underpins serum resistance in extra-intestinal pathogenic Escherichia coli
Open Access
- 23 August 2024
- journal article
- research article
- Published by Microbiology Society in Microbiology
- Vol. 170 (8) , 001493
Abstract
Escherichia coli (E. coli) is a major cause of urinary tract infections, bacteraemia, and sepsis. CFT073 is a prototypic, urosepsis isolate of sequence type (ST) 73. This laboratory, among others, has shown that strain CFT073 is resistant to serum, with capsule and other extracellular polysaccharides imparting resistance. The interplay of such polysaccharides remains under-explored. This study has shown that CFT073 mutants deficient in lipopolysaccharide (LPS) O-antigen and capsule display exquisite serum sensitivity. Additionally, O-antigen and LPS outer core mutants displayed significantly decreased surface K2 capsule, coupled with increased unbound K2 capsule being detected in the supernatant. The R1 core and O6 antigen are involved in the tethering of K2 capsule to the CFT073 cell surface, highlighting the importance of the R1 core in serum resistance. The dependence of capsule on LPS was shown to be post-transcriptional and related to changes in cell surface hydrophobicity. Furthermore, immunofluorescence microscopy suggested that the surface pattern of capsule is altered in such LPS core mutants, which display a punctate capsule pattern. Finally, targeting LPS biosynthesis using sub-inhibitory concentrations of a WaaG inhibitor resulted in increased serum sensitivity and decreased capsule in CFT073. Interestingly, the dependency of capsule on LPS has been observed previously in other Enterobacteria, indicating that the synergy between these polysaccharides is not just strain, serotype or species-specific but may be conserved across several pathogenic Gram-negative species. Therefore, using WaaG inhibitor derivatives to target LPS is a promising therapeutic strategy to reduce morbidity and mortality by reducing or eliminating surface capsule.Keywords
All Related Versions
Funding Information
- National Children's Research Centre (C/18/4)
This publication has 45 references indexed in Scilit:
- Super-Resolution Fluorescence Microscopy Study of the Production of K1 Capsules byEscherichia coli: Evidence for the Differential Distribution of the Capsule at the Poles and the Equator of the CellLangmuir, 2019
- Trends over time in Escherichia coli bloodstream infections, urinary tract infections, and antibiotic susceptibilities in Oxfordshire, UK, 1998–2016: a study of electronic health recordsThe Lancet Infectious Diseases, 2018
- Trends in ExPEC serogroups in the UK and their significanceEuropean Journal of Clinical Microbiology & Infectious Diseases, 2016
- Extra-intestinal pathogenic Escherichia coli (ExPEC): Disease, carriage and clonesJournal of Infection, 2015
- The epidemiology of urinary tract infectionNature Reviews Urology, 2010
- Distribution of lipopolysaccharide core types among avian pathogenic Escherichia coli in relation to the major phylogenetic groupsVeterinary Microbiology, 2008
- Broad-spectrum biofilm inhibition by a secreted bacterial polysaccharideProceedings of the National Academy of Sciences, 2006
- Role of lipopolysaccharide on the structure and function of α-hemolysin from Escherichia coliChemistry and Physics of Lipids, 2005
- Preliminary characterisation of an Escherichia coli K5 lyase-deficient strain producing the K5 polysaccharideBiotechnology Letters, 2004
- Expression of capsular polysaccacharide determines serum resistance in Escherichia coli k92Zentralblatt für Bakteriologie, 1994